Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma
- 212 Downloads
Intracavitary levels of VEGF, bFGF, IL-8 and IL-12 were evaluated by ELISA in 45 patients, 7 with recurrent anaplastic astrocytoma (rAA), 12 with glioblastoma (GBM) and 26 with recurrent glioblastoma (rGBM). In 25 patients plasma levels of the molecules were also quantitated. Twenty-three healthy controls were also studied for plasma concentrations of the same molecules.
Plasma levels of VEGF (mean 33.89 ± 6.71 pg/ml) and bFGF (mean 11.1 ± 3.24 pg/ml) were higher in patients than in controls (mean 16.78 ± 3.7 pg/ml for VEGF, mean 0.21 ± 0.09 pg/ml for bFGF) (p = 0.04 and p = 0.001, respectively) while plasma IL-12 levels were lower (mean 45.6 ± 1.5 pg/ml in patients, mean 79.7 ± 1.3 pg/ml in controls) (p = 0.009).
Intracavitary VEGF levels were 5–53.307 fold higher (mean 90,900 ± 24,789 pg/ml) than in the corresponding plasma. Also IL-8 concentrations were higher in intracavitary fluid (mean 6,349.76 ± 1,460.93 pg/ml) than in plasma (mean 43.44 ± 24.82 pg/ml). Maximum VEGF levels were found in tumor fluid of recurrent glioblastoma patients (mean 147,678 ± 39,903 pg/ml), intermediate levels in glioblastoma patients (mean 20,322 ± 11,892 pg/ml) and lower levels in rAA patients (mean 9,111 ± 5,789 pg/ml). The data also suggest that higher intracavitary levels of VEGF and IL-8, and lower IL-12 levels, may be correlated with shorter adjunctive survival times, but more data will need to be collected to establish this correlation clearly.
Unable to display preview. Download preview PDF.
- 1.Reijneveld JC, Voest E, Taphoorn MJ: Angiogenesis in malignant primary and metastatic brain tumors. J Neurol 247: 597–608, 2000Google Scholar
- 2.Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P: Grading of astrocytomas. A simple and reproducible method. Cancer 62: 2152–2165, 1988Google Scholar
- 3.Carroll RS, Zhang J, Bello L, Melnick MB, Maruyama T, McL Black P: KDR activation in astrocytic neoplasms. Cancer 86: 1335–1341, 1999Google Scholar
- 4.Oehring RD, Miletic M, Valter MM, Pietsch T, Neumann J, Fimmers R, Schlegel U: Vascular endothelial growth factor (VEGF) in astrocytic gliomas - a prognostic factor? J Neuro-Oncology 45: 117–125, 1999Google Scholar
- 5.Stockhammer G, Obgeweser A, Kostron H, Schumacher P, Muigg A, Felber S, Slavc I, Gunsilius E, Gastl G: Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol 100: 101–105, 2000Google Scholar
- 6.Li VW, Folkerth RD, Watanabe H, Yu C, Rupnick M, Barnes P, Scott RM, Black PM, Sallan SE, Folkman J: Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 344: 82–86, 1994Google Scholar
- 7.Kurimoto M, Endo S, Hirashima Y, Nishijima M, Takaku A: Elevated plasma basic fibroblast growth factor in brain tumor patients. Neurol Med Chir (Tokyo) 36: 865–868, 1996Google Scholar
- 8.Stefanik DF, Rizkalla LR, Soi A, Goldblatt SA, Rizkalla WM: Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res 51: 5760–5765, 1991Google Scholar
- 9.Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin 12.J Natl Cancer Inst 87: 581–586, 1995Google Scholar
- 10.Boiardi A, Eoli M, Salmaggi A, Zappacosta B, Fariselli L, Milanesi I, Broggi G, Silvani A: Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. J Neuro-Oncol 54: 39–47, 2001Google Scholar
- 11.Weindel K, Moringlane JR, Marme D, Weich HA: Detection and quantification of vascular endothelial growth factor/ vascular permeability factor in brain tumor tissue and cystic fluid: the key to angiogenesis? Neurosurgery 35: 439–448, 1994Google Scholar
- 12.Yao Y, Kubota K, Sato K, Kitai R, Takeuki H, Arishima H: Prognostic value of vascular endothelial growth factor and its receptos Flt-1 and Flk-1 in astrocytic tumours. Acta Neurochir (Wien) 143: 159–166, 2001Google Scholar
- 13.Poon RT, Fan ST, Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19: 1207–1225, 2001Google Scholar
- 14.Takano S, Yoshii Y, Kondo S, Suzuki H, Maranu T, Shirai S, Nose T: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56: 2185–2190, 1996Google Scholar
- 15.Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L, Mentha G, Ruefenacht D, SappinoAP, Pepper MS: Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 85: 40–45, 2000Google Scholar
- 16.Meliconi R, Pulsatelli L, Dolzani P, Boiardi L, Macchioni P, Salvarani C, Silvestri T, Frizziero L, F acchini A: Vascular endothelial growth factor production in polymialgia rheumatica. Arthritis Rheum 43: 2472–2480, 2000Google Scholar
- 17.Desbaillets I, Diserens AC, de Tribolet N, Hamou MF, Van Meir EG: Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene 18: 1447–1456, 1999Google Scholar
- 18.Dunst J, Pigorsch S, Hansgen G, Hinter I, Lautenschlager C, Becket A: Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther Onkol 175: 93–96, 1999Google Scholar
- 19.LeY JP, Corry M: Hypoxia-induced bFGF gene expression is mediated through the JNK signal transduction pathway. Mol Cell Biochem 202: 1–8, 1999Google Scholar
- 20.Dias S, Boyd R, Balkwill F: IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer 78: 361–365, 1998Google Scholar
- 21.Nakayama Y, Sako T, Shibao K, Onitsuka K, Nagashima N, Hirata K, Nagata N, Itoh H: Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer. Anticancer Res 20: 4097–4102, 2000Google Scholar
- 22.Alessandri G, Chirivì RG, Fiorentini S, Dossi R, Bonardelli S, Giulini SM, Landoni F, Graziotti PP, Turano A, Caruso A, Zardi L, Giavazzi R, Bani MR: Phenotypic and functional characteristics of tumour-derived microvascular endothelial cells. Clin Exp Metastasis 17: 655–662, 1999Google Scholar